Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Xoma Royalty Corporation (XOMA)

Xoma Royalty Corporation (XOMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 240,785
  • Shares Outstanding, K 11,783
  • Annual Sales, $ 4,760 K
  • Annual Income, $ -40,830 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta 1.00
  • Price/Sales 24.44
  • Price/Cash Flow N/A
  • Price/Book 2.80

Options Overview Details

View History
  • Implied Volatility 104.87% ( +4.72%)
  • Historical Volatility 43.49%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 104.87% on 03/11/25
  • IV Low 44.82% on 06/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 98
  • Open Int (30-Day) 102

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.47
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +40.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.92 +2.59%
on 03/10/25
26.82 -23.81%
on 02/18/25
-6.33 (-23.64%)
since 02/14/25
3-Month
19.92 +2.59%
on 03/10/25
29.02 -29.58%
on 01/15/25
-6.72 (-24.73%)
since 12/13/24
52-Week
19.92 +2.59%
on 03/10/25
35.00 -41.61%
on 11/27/24
-5.34 (-20.70%)
since 03/14/24

Most Recent Stories

More News
Bank Rate Decision Due Next Week

U.S. Monday Featured Earnings Oracle Corporation (NYSE:ORCL) (Q3) EPS of $1.18, compared ...

BEKE : 24.39 (+8.69%)
XOMA : 20.43 (+0.81%)
ULTA : 357.48 (+13.68%)
EVEX : 3.19 (-2.74%)
MTN : 159.57 (-0.10%)
CCI : 103.22 (+10.37%)
ORCL : 149.27 (+1.09%)
DKS : 194.50 (+4.26%)
ENGH.TO : 26.11 (+1.28%)
BNTX : 99.47 (+2.06%)
GOGO : 6.86 (-0.15%)
FERG : 159.90 (+3.11%)
XOMA Royalty to Present at Investor Conferences in March

XOMA : 20.43 (+0.81%)
XOMAP : 25.60 (+0.23%)
XOMAO : 25.41 (-0.03%)
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA : 20.43 (+0.81%)
XOMAP : 25.60 (+0.23%)
XOMAO : 25.41 (-0.03%)
XOMA Royalty Corporation Announces Cash Dividends for Series A and Series B Preferred Stock

XOMA Royalty Corporation announces upcoming cash dividends for Series A and B Preferred Stock, payable January 15, 2025.Quiver AI SummaryXOMA Royalty Corporation has announced that its Board of Directors...

XOMA : 20.43 (+0.81%)
XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA : 20.43 (+0.81%)
XOMAP : 25.60 (+0.23%)
XOMAO : 25.41 (-0.03%)
XOMA Royalty Acquires Pulmokine, Adding Seralutinib as its Seventh Phase 3 Royalty Asset

XOMA Royalty acquires seralutinib, enhancing its Phase 3 royalty assets targeting pulmonary arterial hypertension.Quiver AI SummaryXOMA Royalty Corporation has acquired an economic interest in seralutinib,...

XOMA : 20.43 (+0.81%)
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

XOMA : 20.43 (+0.81%)
XOMAP : 25.60 (+0.23%)
XOMAO : 25.41 (-0.03%)
XOMA Royalty: Q3 Earnings Snapshot

XOMA Royalty: Q3 Earnings Snapshot

XOMA : 20.43 (+0.81%)
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA : 20.43 (+0.81%)
XOMAP : 25.60 (+0.23%)
XOMAO : 25.41 (-0.03%)
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA : 20.43 (+0.81%)
XOMAP : 25.60 (+0.23%)
XOMAO : 25.41 (-0.03%)

Business Summary

XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE,...

See More

Key Turning Points

3rd Resistance Point 21.32
2nd Resistance Point 20.94
1st Resistance Point 20.69
Last Price 20.43
1st Support Level 20.06
2nd Support Level 19.69
3rd Support Level 19.43

See More

52-Week High 35.00
Fibonacci 61.8% 29.24
Fibonacci 50% 27.46
Fibonacci 38.2% 25.68
Last Price 20.43
52-Week Low 19.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar